Jeffrey M. Statland

Jeffrey M. Statland, M.D., is a Professor of Neurology at the University of Kansas School of Medicine, where he serves as co-Principal Investigator of the FSHD Clinical Trial Research Network—a collaborative initiative spanning 15 institutions across the United States and European Union. Board certified by the American Board of Psychiatry and Neurology, he directs neuromuscular clinical research and patient care within the Department of Neurology.

Dr. Statland's academic foundation includes a BA in Literature from Sarah Lawrence College, an MFA from Emerson College, and an MD from the University of Kansas School of Medicine. His clinical training encompassed neurology residency at the University of Kansas Medical Center followed by a fellowship in experimental therapeutics at the University of Rochester Medical Center.

His research centers on neuromuscular disease natural history and therapeutic development, with decade-long specialization in Facioscapulohumeral Muscular Dystrophy (FSHD). He pioneered novel outcome measures for FSHD clinical trials, including patient-reported burden assessments and physiological biomarkers. His work extends to Duchenne Muscular Dystrophy, ALS, Spinal Muscular Atrophy, and Myotonic Dystrophy through collaborations with consortia like GRASP and HEALEY ALS Platform.

Recent publications reveal his leadership in biomarker validation (e.g., SLC34A2 for FSHD), advanced imaging techniques (quantitative MRI), and adaptive trial design. His work consistently addresses critical gaps in endpoint selection, patient stratification, and multi-center coordination for rare neuromuscular disorders.

While Dr. Statland's leadership in clinical research networks is prominent, no specific scientific awards or fellowships are documented in the provided materials.

He actively mentors neurology trainees and secures substantial grant funding for neuromuscular research. His role as co-PI of the FSHD Clinical Trial Research Network drives multi-institutional studies, while collaborations with GRASP Consortium and HEALEY ALS Platform expand his impact across neuromuscular disease domains.

Within the Department of Neurology, Dr. Statland co-leads the Neuromuscular Group and directs the FSHD Clinical Trial Research Network. His team integrates clinical care, natural history studies, and therapeutic development, maintaining active partnerships with the Myotonic Dystrophy Foundation and American Association of Neuromuscular and Electrodiagnostic Medicine.